Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001847367-25-000035
Filing Date
2025-06-30
Accepted
2025-06-30 16:19:18
Documents
16
Period of Report
2025-05-21
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A alms-20250521x8ka.htm   iXBRL 8-K/A 44089
2 EX-23.1 alms-20250521xex23d1.htm EX-23.1 2654
3 EX-99.1 alms-20250521xex99d1.htm EX-99.1 821419
4 EX-99.2 alms-20250521xex99d2.htm EX-99.2 600061
5 EX-99.3 alms-20250521xex99d3.htm EX-99.3 649029
  Complete submission text file 0001847367-25-000035.txt   2404429

Data Files

Seq Description Document Type Size
6 EX-101.SCH alms-20250521.xsd EX-101.SCH 3261
7 EX-101.LAB alms-20250521_lab.xml EX-101.LAB 15917
8 EX-101.PRE alms-20250521_pre.xml EX-101.PRE 10317
18 EXTRACTED XBRL INSTANCE DOCUMENT alms-20250521x8ka_htm.xml XML 4852
Mailing Address 280 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 280 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 650-231-6625
ALUMIS INC. (Filer) CIK: 0001847367 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-42143 | Film No.: 251092305
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)